Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,816.89
(
-0.11%
)
US TECH 100
24,499.60
(
0.38%
)
Dow Jones
47,916.57
(
-0.56%
)
Brent Oil
92.41
(
0.00%
)
Bitcoin
72,752.00
(
-0.31%
)
News Focus
News Focus
Post# of 257382
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122860
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Titan V post# 222352

Monday, 12/03/2018 7:46:47 AM

Monday, December 03, 2018 7:46:47 AM

Post# of 257382
GSK acquires TSRO for $75/sh cash—a 182% premium relative to TSRO’s closing price on 11/15/18, the day before Bloomberg cited M&A discussions (#msg-144945059):

https://finance.yahoo.com/news/gsk-reaches-agreement-acquire-tesaro-120400498.html

TSRO’s main asset is Zejula (one of three approved PARP inhibitors), which is currently selling at an annualized rate of ~$250M based on a narrow label that will likely be expanded.

The nominal deal value is $5.1B.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Unleash the power of Level 2

Spot liquidity moves with access to US order books.

Sign Up